Arca
Skip to content
Tools
Tools

Transplantation

Drug research and approvals for transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,565 studies of transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 69 drug trials for it since 2013, FDA has 16 approved and 83 open orphan designations naming it, and the EU has 30 authorised medicines for it.

  • Recruiting worldwide: 1,565
  • Trials authorized in Canada: 69
  • FDA orphan approvals: 16
  • EU medicines: 30

Recruiting now

Newest posted first, of 1,565 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 69; search them all in Canada trials
Aug 27, 2026A multicenter, phase 3 randomized, active-controlled, open-label study to evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult…Tegoprubart (AT-1501)Eledon PharmaceuticalsPending
Aug 24, 2026An adaptive, randomised controlled trial to treat polyomavirus infections (BKPYV) in kidney and kidney-pancreas transplant recipientsGamunex / IgivnexUniversity of QueenslandPending
Apr 8, 2026Expanded antimicrobial prophylaxis to reduce surgical site infections in liver transplant recipientsMeropenem / Vancomycin / Daptomycin / FluconazoleUniversity Health NetworkOngoing
Mar 4, 2026An open-label long term extension (LTE) study for felzartamab studies in solid organ transplantFelzartamabBiogenPending
Feb 25, 2026Advancing transplantation outcomes in childrenNulojix / RapamuneNational Institute of Allergy and Infectious Diseases (Niaid)Ongoing
Jan 6, 2026Renal ex vivo SYN002 perfusion to eliminate cmv transmission: a pilot safety trial in kidney transplant recipients. (short title: respect-cmv trial)SYN002University Health Network Ajmera Transplant CentrePending
Nov 26, 2025A seamless phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant and safety of…Frexalimab (SAR441344)Sanofi-Aventis Canada IncOngoing
Oct 30, 2025A double-blind, placebo-controlled, multicenter, randomized phase 2 trial evaluating the efficacy and safety of felzartamab in recipients of kidney transplants…FelzartamabBiogenOngoing
Jun 19, 2025A phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted rsvpref3 vaccine and the…Bio RSV oa=adj (GSK3844766A)GSKOngoing
Apr 16, 2025Semaglutide for the prevention of post-transplant diabetes mellitus in kidney transplant recipientsRybelsus (semaglutide)University Health NetworkOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 99
Jun 30, 2026TregziFor use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic…Orca Biosystems, Inc.Approved
Dec 9, 2025WaskyraTreatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene…Fondazione Telethon ETSApproved
Jan 21, 2025GrafapexIn combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric…Medac GmbHApproved
Sep 8, 2023AphexdaIn combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent…Ayrmid Pharma Ltd.Approved
Apr 17, 2023OmisirgeFor use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood…Gamida Cell Ltd.Approved
Jul 16, 2021PrografProphylaxis of organ rejection in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, heart transplant,…Astellas Pharma Global Development, Inc.Approved
Apr 25, 2017OpdivoTreatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell…Bristol-Myers Squibb CompanyApproved
Feb 22, 2017RevlimidTreatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)Celgene CorporationApproved
Jan 26, 2017TepadinaIndicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative…Adienne S.A.Approved
May 17, 2016OpdivoTreatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell…Bristol-Myers Squibb CompanyApproved
Mar 10, 2016EvomelaFor high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myelomaAcrotech Biopharma LLCApproved
Aug 17, 2015AdcetrisTreatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell…Seagen Inc.Approved
Dec 15, 2008Mozobil (r)To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in…Genzyme CorporationApproved
Apr 6, 2007HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patientsCangene CorporationApproved
Feb 4, 1999BusulfexFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation…Otsuka Pharmaceutical Company, LtdApproved

Medicines authorised in the EU

Newest first; 15 of 30
Jan 9, 2026WaskyraEtuvetidigene autotemcel · orphanFondazione Telethon ETSEMA ↗
Aug 25, 2025ZemcelproAllogeneic umbilical cord-derived CD34- cells, non-expanded; dorocubicel · orphanCordex Biologics International LimitedEMA ↗
Feb 9, 2024CasgevyExagamglogene autotemcel · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Jan 5, 2024Azacitidine KabiAzacitidine · genericFresenius Kabi Deutschland GmbHEMA ↗
Mar 26, 2021Thiotepa RiemserThiotepa · genericEsteve Pharmaceuticals GmbHEMA ↗
Feb 11, 2021Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)Lenalidomide · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Dec 18, 2020Lenalidomide MylanLenalidomide · genericMylan Pharmaceuticals LimitedEMA ↗
Mar 27, 2020Azacitidine MylanAzacitidine · genericMylan Pharmaceuticals LimitedEMA ↗
Mar 24, 2020Azacitidine betapharmAzacitidine · genericbetapharm Arzneimittel GmbHEMA ↗
Feb 13, 2020Azacitidine AccordAzacitidine · genericAccord Healthcare S.L.U.EMA ↗
Jun 20, 2019TrecondiTreosulfanmedac Gesellschaft für klinische Spezialpräparate mbHEMA ↗
Sep 20, 2018Lenalidomide AccordLenalidomide · genericAccord Healthcare S.L.U.EMA ↗
Dec 8, 2017TacforiusTacrolimus · genericTeva B.V.EMA ↗
Feb 17, 2015HoloclarEx vivo expanded autologous human corneal epithelial cells containing stem cellsHolostem s.r.l.EMA ↗
Sep 22, 2014Busulfan Fresenius KabiBusulfan · genericFresenius Kabi Deutschland GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.